Abrupt switching from venlafaxine to duloxetine in the treatment of major depressive disorder

被引：0
作者：
Perahia, DGS
Kajdasz, DK
Barradell, C
Gandhi, P
Wohlreich, M
Fava, M
机构：
[1] Lilly Res Ctr Ltd, Surrey, England
[2] Gordon Hosp, London, England
[3] Lilly Res Labs, Indianapolis, IN USA
[4] Eli Lilly & Co, Basingstoke, Hants, England
[5] Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, Boston, MA 02114 USA
来源：
JOURNAL OF PSYCHOPHARMACOLOGY | 2005年 / 19卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A46 / A46
页数：1
相关论文
共 50 条
[41]   Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder [J].
Khandker, Rezaul K. ;
Kruzikas, Denise T. ;
McLaughlin, Trent P. .
JOURNAL OF MANAGED CARE PHARMACY, 2008, 14 (05) :426-441
[42]   Venlafaxine versus sertraline for major depressive disorder [J].
Wise, TN ;
Sheridan, MJ .
JOURNAL OF CLINICAL PSYCHIATRY, 2000, 61 (11) :873-874
[43]   Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases [J].
Wang, Junling ;
Liu, Xianchen ;
Mullins, C. Daniel .
CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (07) :1303-1313
[44]   Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder [J].
Harada, Eiji ;
Shirakawa, Osamu ;
Satoi, Yoichi ;
Marangell, Lauren B. ;
Escobar, Rodrigo .
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2016, 12 :89-97
[45]   Duloxetine 60 mg once daily in the treatment of milder major depressive disorder [J].
Perahia, DGS ;
Kajdasz, DK ;
Walker, DJ ;
Raskin, J ;
Tylee, A .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (05) :613-620
[46]   Effects of Duloxetine Treatment on Brain Response to Painful Stimulation in Major Depressive Disorder [J].
Lopez-Sola, Marina ;
Pujol, Jesus ;
Hernandez-Ribas, Rosa ;
Harrison, Ben J. ;
Contreras-Rodriguez, Oren ;
Soriano-Mas, Carles ;
Deus, Joan ;
Ortiz, Hector ;
Menchon, Jose M. ;
Vallejo, Julio ;
Cardoner, Narcis .
NEUROPSYCHOPHARMACOLOGY, 2010, 35 (11) :2305-2317
[47]   TREATMENT PERSISTENCE WITH DULOXETINE AND HEALTH CARE COSTS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER [J].
Liu, X. ;
Tepper, P. ;
Mullins, C. D. .
VALUE IN HEALTH, 2010, 13 (03) :A112-A113
[48]   Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials [J].
Lam, Raymond W. ;
Andersen, Henning F. ;
Wade, Alan G. .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2008, 23 (04) :181-187
[49]   Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial [J].
Goldstein, DJ ;
Mallinckrodt, C ;
Lu, YL ;
Demitrack, MA .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (03) :225-231
[50]   Effects of Duloxetine Treatment on Brain Response to Painful Stimulation in Major Depressive Disorder [J].
Marina López-Solà ;
Jesus Pujol ;
Rosa Hernández-Ribas ;
Ben J Harrison ;
Oren Contreras-Rodríguez ;
Carles Soriano-Mas ;
Joan Deus ;
Héctor Ortiz ;
José M Menchón ;
Julio Vallejo ;
Narcís Cardoner .
Neuropsychopharmacology, 2010, 35 :2305-2317
12345